FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295512> ?p ?o ?g. }

• W4286295512 endingPage "TPS3157" @default.
• W4286295512 startingPage "TPS3157" @default.
• W4286295512 abstract "TPS3157 Background: Kidney associated antigen 1 (KAAG1) is highly and selectively expressed on tumor cell surface, such as ovarian, prostate, and triple negative breast cancers (TNBC), and is rapidly internalized and co-localized with a lysosomal marker, making an ideal candidate for an antibody-drug conjugate (ADC) target. ADCT-901 is an ADC composed of a humanized monoclonal antibody IgG1 against KAAG1, conjugated through a cathepsin-cleavable linker to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin. In mouse xenograft models of human-derived TNBC, ovarian, and renal cancers significant tumor reduction was observed after a single dose of ADCT-901, providing the rationale for clinical development of a PBD-based ADC to treat KAAG1 expressing tumors (Zammarchi et al, AACR 2019). This study aims to identify the recommended dose and schedule for expansion and to characterize safety and tolerability of ADCT-901 in patients (pts) with selected advanced solid tumors that generally express KAAG1. Methods: ADCT-901-101 is a phase 1, multicenter, 2-part, open-label study that will enroll ̃70 pts (NCT04972981). Part 1: pts will receive escalating doses of ADCT-901 guided by a 3+3 design (1st dose: 15 µg/kg every 3 weeks [Q3W]; highest dose: 290 µg/kg Q3W). Dose escalation will be evaluated by administering the lowest dose to first 3 pts, then increasing/decreasing the dose based on dose-limiting toxicity (DLT) experienced by pts. The dose and schedule of ADCT-901 identified in part 1 will be tested in part 2 to characterize safety, tolerability, and preliminary efficacy of ADCT-901. Primary endpoints include incidence of DLTs (part 1 only), frequency/severity of adverse events (AE) and serious AE, clinically significant changes in vitals, laboratory values, overall tolerability, and frequency of dose interruptions and reductions. Secondary endpoints include overall response rate, duration of response, progression-free and overall survival, pharmacokinetic parameters of ADCT-901 total antibody, PBD-conjugated antibody, unconjugated SG3199 in serum, and frequency of confirmed positive antidrug antibody responses. Exploratory endpoints include tumor modulation and potential pharmacodynamic changes. Key inclusion criteria: pathologic diagnosis of selected solid tumor (cholangiocarcinoma, renal cell carcinoma, ovarian/fallopian tube and prostate cancers, TNBC) locally advanced or metastatic at time of screening, pts refractory or intolerant to existing therapy, tissue biopsy or available tissue sample, ECOG of 0-2, and adequate organ function based on predefined laboratory parameters. Pts with symptomatic CNS metastases and clinically significant third space fluid accumulation will be excluded. The study opened for recruitment in September 2021; enrollment is ongoing. Funding: ADC Therapeutics; medical writing: CiTRUS Health Group. Clinical trial information: NCT04972981." @default.
• W4286295512 created "2022-07-21" @default.
• W4286295512 creator A5014584439 @default.
• W4286295512 creator A5022546842 @default.
• W4286295512 creator A5036587861 @default.
• W4286295512 creator A5043235685 @default.
• W4286295512 creator A5046116136 @default.
• W4286295512 creator A5063897579 @default.
• W4286295512 creator A5068433389 @default.
• W4286295512 creator A5069777765 @default.
• W4286295512 creator A5090621600 @default.
• W4286295512 date "2022-06-01" @default.
• W4286295512 modified "2023-09-26" @default.
• W4286295512 title "First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors." @default.
• W4286295512 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps3157" @default.
• W4286295512 hasPublicationYear "2022" @default.
• W4286295512 type Work @default.
• W4286295512 citedByCount "0" @default.
• W4286295512 crossrefType "journal-article" @default.
• W4286295512 hasAuthorship W4286295512A5014584439 @default.
• W4286295512 hasAuthorship W4286295512A5022546842 @default.
• W4286295512 hasAuthorship W4286295512A5036587861 @default.
• W4286295512 hasAuthorship W4286295512A5043235685 @default.
• W4286295512 hasAuthorship W4286295512A5046116136 @default.
• W4286295512 hasAuthorship W4286295512A5063897579 @default.
• W4286295512 hasAuthorship W4286295512A5068433389 @default.
• W4286295512 hasAuthorship W4286295512A5069777765 @default.
• W4286295512 hasAuthorship W4286295512A5090621600 @default.
• W4286295512 hasConcept C121608353 @default.
• W4286295512 hasConcept C126322002 @default.
• W4286295512 hasConcept C143998085 @default.
• W4286295512 hasConcept C159654299 @default.
• W4286295512 hasConcept C197934379 @default.
• W4286295512 hasConcept C203014093 @default.
• W4286295512 hasConcept C2776146153 @default.
• W4286295512 hasConcept C2777325958 @default.
• W4286295512 hasConcept C2778375690 @default.
• W4286295512 hasConcept C2780110267 @default.
• W4286295512 hasConcept C530470458 @default.
• W4286295512 hasConcept C542903549 @default.
• W4286295512 hasConcept C71924100 @default.
• W4286295512 hasConcept C98274493 @default.
• W4286295512 hasConceptScore W4286295512C121608353 @default.
• W4286295512 hasConceptScore W4286295512C126322002 @default.
• W4286295512 hasConceptScore W4286295512C143998085 @default.
• W4286295512 hasConceptScore W4286295512C159654299 @default.
• W4286295512 hasConceptScore W4286295512C197934379 @default.
• W4286295512 hasConceptScore W4286295512C203014093 @default.
• W4286295512 hasConceptScore W4286295512C2776146153 @default.
• W4286295512 hasConceptScore W4286295512C2777325958 @default.
• W4286295512 hasConceptScore W4286295512C2778375690 @default.
• W4286295512 hasConceptScore W4286295512C2780110267 @default.
• W4286295512 hasConceptScore W4286295512C530470458 @default.
• W4286295512 hasConceptScore W4286295512C542903549 @default.
• W4286295512 hasConceptScore W4286295512C71924100 @default.
• W4286295512 hasConceptScore W4286295512C98274493 @default.
• W4286295512 hasIssue "16_suppl" @default.
• W4286295512 hasLocation W42862955121 @default.
• W4286295512 hasOpenAccess W4286295512 @default.
• W4286295512 hasPrimaryLocation W42862955121 @default.
• W4286295512 hasRelatedWork W2048097813 @default.
• W4286295512 hasRelatedWork W2081385214 @default.
• W4286295512 hasRelatedWork W2159173527 @default.
• W4286295512 hasRelatedWork W2358863311 @default.
• W4286295512 hasRelatedWork W2386398244 @default.
• W4286295512 hasRelatedWork W2409130183 @default.
• W4286295512 hasRelatedWork W2413699619 @default.
• W4286295512 hasRelatedWork W2969853760 @default.
• W4286295512 hasRelatedWork W3205539032 @default.
• W4286295512 hasRelatedWork W4224992756 @default.
• W4286295512 hasVolume "40" @default.
• W4286295512 isParatext "false" @default.
• W4286295512 isRetracted "false" @default.
• W4286295512 workType "article" @default.